Drug
Fragmin
Fragmin is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_3
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (50.0%)
Phase 32 (50.0%)
Trials by Status
unknown125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
unknownphase_2
A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement
NCT05189002
completedphase_3
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
NCT00006083
completedphase_3
Use Of Fragmin In Hemodialysis
NCT01879618
completedphase_2
The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
NCT00765063
Clinical Trials (4)
Showing 4 of 4 trials
NCT05189002Phase 2
A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement
NCT00006083Phase 3
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
NCT01879618Phase 3
Use Of Fragmin In Hemodialysis
NCT00765063Phase 2
The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4